Free Trial
→ This next market event could mean total financial ruin for some (From Weiss Ratings) (Ad)tc pixel
NASDAQ:ONCO

Onconetix 12/9/2024 Earnings Report

Onconetix logo
$0.34 -0.04 (-9.89%)
As of 12:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Onconetix EPS Results

Actual EPS
-$952.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Onconetix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Onconetix Announcement Details

Quarter
Date
12/9/2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Onconetix Earnings Headlines

Onconetix Inc. Reports New Clinical Data Supporting Proclarix® in Reducing Overdiagnosis and Launches PRIME Study with Labcorp
May 13, 2026  |  quiverquant.comQ
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
May 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/13/3294088/0/en/onconetix-reports-q1-2026-progress-at-proteomedix-ag-including-two-new-peer-reviewed-publications-and-initiation-of-u-s-validation-study.html
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
May 18 at 1:00 AM  |  Reagan Gold Group (Ad)
Onconetix Shareholders Approve Flexible Reverse Stock Split Authorization
May 8, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1724138/onconetix-shareholders-approve-flexible-reverse-stock-split-authorization/
Onconetix Reshapes Board Leadership With New Chairman, Director
April 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/onconetix-reshapes-board-leadership-with-new-chairman-director?utm_source=marketbeat.com&utm_medium=referral
Onconetix: HRT financial, 10% owner, sells $110,169 in stock
April 23, 2026  |  investing.comhttps://www.investing.com/news/insider-trading-news/onconetix-hrt-financial-10-owner-sells-110169-in-stock-93CH-4627215
See More Onconetix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Onconetix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Onconetix and other key companies, straight to your email.

About Onconetix

Onconetix (NASDAQ:ONCO), a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

View Onconetix Profile
Earnings Tools